---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-27T14:22:07.248887'
end_time: '2025-12-27T14:29:26.248411'
duration_seconds: 439.0
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: RAB7B
  gene_symbol: RAB7B
  uniprot_accession: Q96AH8
  protein_description: 'RecName: Full=Ras-related protein Rab-7b;'
  gene_info: Name=RAB7B;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the small GTPase superfamily. Rab family.
  protein_domains: P-loop_NTPase. (IPR027417); Small_GTP-bd. (IPR005225); Small_GTPase.
    (IPR001806); Ras (PF00071)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 12
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96AH8
- **Protein Description:** RecName: Full=Ras-related protein Rab-7b;
- **Gene Information:** Name=RAB7B;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the small GTPase superfamily. Rab family.
- **Key Domains:** P-loop_NTPase. (IPR027417); Small_GTP-bd. (IPR005225); Small_GTPase. (IPR001806); Ras (PF00071)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "RAB7B" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'RAB7B' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **RAB7B** (gene ID: RAB7B, UniProt: Q96AH8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q96AH8
- **Protein Description:** RecName: Full=Ras-related protein Rab-7b;
- **Gene Information:** Name=RAB7B;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the small GTPase superfamily. Rab family.
- **Key Domains:** P-loop_NTPase. (IPR027417); Small_GTP-bd. (IPR005225); Small_GTPase. (IPR001806); Ras (PF00071)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "RAB7B" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'RAB7B' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **RAB7B** (gene ID: RAB7B, UniProt: Q96AH8) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan
- Verify identity and core definitions for human RAB7B (UniProt Q96AH8), a small GTPase of the Rab family, and set scope distinguishing it from RAB7A.
- Gather recent (especially 2023–2024) and foundational primary literature on molecular function, subcellular localization, effectors/regulators, and pathway roles.
- Extract precise experimental evidence: trafficking routes, innate immune receptor trafficking, actomyosin links and migration phenotypes, key regulators (GAPs/GEFs), and quantitative metrics (colocalization, kinetics, phenotypes).
- Synthesize recent developments and translational links (disease associations, applications).
- Compile a comprehensive, well-cited report with URLs and publication dates.

Identity verification and key concepts
- Target: human RAB7B, UniProt Q96AH8; Ras-related protein Rab-7b. This protein is a small GTPase of the Rab family that cycles between GDP/GTP-bound states to regulate membrane trafficking. Multiple human cell systems explicitly study “human Rab7b,” including HeLa, MelJuSo, and monocyte-derived dendritic cells (MDDCs), confirming the human identity and Rab superfamily membership (Journal of Cell Science, Nov 2014, https://doi.org/10.1242/jcs.155861; Journal of Cell Science, Sep 2018, https://doi.org/10.1242/jcs.216630) (borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2).
- Family/domains alignment: Functional studies explicitly describe Rab7b as a small GTPase, consistent with P-loop NTPase/Ras superfamily architecture (J Cell Sci 2014; J Cell Sci 2018) (borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2).

1) Key concepts and definitions with the current understanding
- Molecular role: Rab7b is a small GTPase that regulates late endosomal traffic and retrograde transport to the trans-Golgi network (TGN). Foundational mechanistic work demonstrates that Rab7b localizes to late endosomes/lysosomes and the Golgi/TGN and controls transport between late endosomes and the TGN (J Cell Sci, 2014, https://doi.org/10.1242/jcs.155861; J Cell Sci, 2018, https://doi.org/10.1242/jcs.216630) (borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2).
- Distinction from Rab7a (conceptual): Rab7a is a master regulator of late endosome–lysosome fusion and autophagy/lysosome function with a broad effector network (e.g., RILP, ORP1L, FYCO1, HOPS, Mon1/Ccz1, retromer), whereas Rab7b has a distinct subcellular routing emphasis toward endosome→TGN transport and has unique interactions (e.g., myosin II, TBC1D5 as a Rab7b GAP) (Biomedical Reviews, Dec 2014, https://doi.org/10.14748/bmr.v25.1049; J Cell Sci, 2018, https://doi.org/10.1242/jcs.216630) (basuray2014rab7athemaster pages 4-7, distefano2018tbc1d5controlsthe pages 1-2, distefano2018tbc1d5controlsthe pages 3-6).

2) Molecular function, regulators/effectors, and quantitative data
- Confirmed molecular functions:
  - Endosome↔TGN trafficking: Rab7b controls transport between late endosomes and the TGN; Rab7b-positive structures are Lamp-1+ late endosomes and Golgi/TGN compartments (J Cell Sci, 2014, 2018; URLs above) (borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2, distefano2018tbc1d5controlsthe pages 3-6).
  - Direct actomyosin linkage: A yeast two-hybrid screen identified myosin II as a Rab7b interactor; endogenous Rab7b co-immunoprecipitates with myosin II in human MDDCs; purified recombinant proteins show direct binding (J Cell Sci, 2014) (borg2014anovelinteraction pages 1-2).
- Key effectors/regulators:
  - TBC1D5 is a GAP for Rab7b: siRNA screening, in vitro GTPase assays (purified TBC1D5), and retromer (VPS35/VPS29)–augmented GAP activity demonstrate that TBC1D5 catalyzes Rab7b GTP hydrolysis and modulates Rab7b cycling on Golgi/late endosomal membranes (J Cell Sci, Sep 2018, https://doi.org/10.1242/jcs.216630) (distefano2018tbc1d5controlsthe pages 1-2, distefano2018tbc1d5controlsthe pages 3-6).
  - Myosin II (actomyosin) functions as a motor/partner: Myosin II depletion or pharmacologic inhibition causes perinuclear clustering/enlargement of Rab7b+ late endosomes and strongly reduces their motility (J Cell Sci, Nov 2014) (borg2014anovelinteraction pages 4-7).
- Quantitative metrics (selected):
  - Colocalization: ~69% of Rab7b vesicles colocalize with myosin II (n>100 vesicles analyzed) (J Cell Sci, 2014) (borg2014anovelinteraction pages 4-7).
  - Vesicle motility velocities: untreated ~0.34 μm/s; reduced to ~0.19 μm/s with myosin II inhibitor mix (ML7+Y27632); ~0.08 μm/s with blebbistatin; effects reversible upon washout and specific to Rab7b (J Cell Sci, 2014) (borg2014anovelinteraction pages 4-7).
  - FRAP kinetics: membrane-binding recovery half-time (t1/2) for Rab7b alone 19.01 ± 0.57 s vs 26.25 ± 0.87 s when co-expressing TBC1D10A (which is not a Rab7b GAP), consistent with distinct cycling regulation (J Cell Sci, 2018) (distefano2018tbc1d5controlsthe pages 3-6).

3) Subcellular localization and trafficking routes controlled
- Localization: Rab7b resides at late endosomes/lysosomes and the Golgi/TGN in human cells (HeLa, MelJuSo, human MDDCs) (J Cell Sci, 2014; J Cell Sci, 2018) (borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2).
- Trafficking routes: Rab7b governs transport from late endosomes to the TGN (retrograde route), functionally distinct from Rab7a’s strong role in late endosome→lysosome maturation and autophagy/lysosome function (J Cell Sci, 2014; J Cell Sci, 2018; Biomedical Reviews, 2014) (borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2, basuray2014rab7athemaster pages 4-7).

4) Roles in innate immunity receptor trafficking and signaling
- Multiple studies implicate Rab7b in limiting TLR signaling by promoting receptor trafficking toward degradation and/or retrograde routes. While early sentinel work on TLR4/TLR9 negative regulation by Rab7b is older, a 2014–2018 mechanistic framework places Rab7b at late endosomes and the TGN, with the machinery (actomyosin, TBC1D5/retromer) to influence receptor recycling versus degradation decisions. In the human platelet and immune-cell context, Rab7b’s regulation of late endosome/TGN sorting and actomyosin-dependent vesicle transport provides a mechanistic basis for negative regulation of activated receptor pools, although the most precise human TLR4 degradation data predate 2020 (see also sections above on localization, motors, and GAP regulation) (borg2014anovelinteraction pages 1-2, borg2014anovelinteraction pages 4-7, distefano2018tbc1d5controlsthe pages 1-2).

5) Interactions with the actomyosin system and impacts on cell migration
- Direct physical interaction with myosin II: Rab7b binds myosin II (validated by Y2H, co-IP of endogenous proteins in human MDDCs, and recombinant pull-downs), indicating myosin II acts as an effector/motor for Rab7b-positive endosomes (J Cell Sci, 2014) (borg2014anovelinteraction pages 1-2).
- Cell migration and cytoskeletal phenotypes: Rab7b depletion reduces stress-fiber formation, cell adhesion on fibronectin, and delays migration; mechanistically, Rab7b depletion lowers GTP-RhoA and decreases phosphorylated myosin light chain (MLC), linking Rab7b to contractility regulation (J Cell Sci, 2014) (borg2014anovelinteraction pages 1-2).
- Quantitative transport phenotypes: Myosin II inhibition markedly reduces Rab7b vesicle velocities and causes perinuclear clustering/enlargement of Lamp-1+ late endosomes, without comparable effects on Rab5, Rab7a, or Rab9 compartments, underscoring specificity (J Cell Sci, 2014) (borg2014anovelinteraction pages 4-7).

6) Distinctions from RAB7A (clear mechanistic contrasts)
- Localization and route preference: Rab7a—late endosome→lysosome fusion/maturation and broad lysosome function; Rab7b—late endosome↔TGN retrograde traffic, with strong Golgi/TGN association (Biomedical Reviews, 2014; J Cell Sci, 2014; J Cell Sci, 2018) (basuray2014rab7athemaster pages 4-7, borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2).
- Effector/regulator sets: Rab7a’s canonical effectors include RILP, ORP1L, FYCO1, HOPS, Mon1/Ccz1 and others; Rab7b is regulated by TBC1D5 as a GAP and engages myosin II as a direct binding partner/effector (Biomedical Reviews, 2014; J Cell Sci, 2018; J Cell Sci, 2014) (basuray2014rab7athemaster pages 4-7, distefano2018tbc1d5controlsthe pages 1-2, borg2014anovelinteraction pages 1-2).
- Functional outcomes: Rab7a broadly controls lysosomal degradation, autophagy-lysosome fusion and receptor downregulation; Rab7b fine-tunes late endosome→TGN routing and couples endosomal transport to actomyosin and migration programs (Biomedical Reviews, 2014; J Cell Sci, 2014; J Cell Sci, 2018) (basuray2014rab7athemaster pages 4-7, borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2).

7) Recent developments and latest research (2023–2024 priority), applications and disease links
- Adipocyte autophagy/lipid metabolism axis (2024): A study in Autophagy (Apr 2024) shows that TIGAR overexpression elevates LRRK2 and drives its interaction with RAB7B in adipocytes, suppressing lysosomal degradation of lipid droplets and impairing macroautophagy and chaperone-mediated autophagy. Mechanistically, active RAB7B in lipid-droplet fractions declines ~2–3× upon TIGAR overexpression (RILP-affinity assay). Pharmacologic inhibition of LRRK2 (ML282) or adipose-targeted delivery of a LRRK2 inhibitor (DNL201 nanoemulsion) reverses lipid accumulation and restores autophagy markers in mice, indicating a functional LRRK2–RAB7B axis and nominating RAB7B as a node in metabolic disease biology and a potential therapeutic target (Autophagy, Apr 2024, https://doi.org/10.1080/15548627.2024.2338576) (zhang2024tigarexacerbatesobesity pages 12-15).
- Regulation by GAPs (2018 foundation for current work): TBC1D5 is a Rab7b GAP whose activity is augmented by retromer, providing a mechanistic handle for modulating Rab7b cycling in cells—relevant for ongoing efforts that exploit retromer- and GAP-dependent endosomal routing in disease models (J Cell Sci, 2018, https://doi.org/10.1242/jcs.216630) (distefano2018tbc1d5controlsthe pages 1-2, distefano2018tbc1d5controlsthe pages 3-6).

8) Current applications and real-world implementations
- Targeting the LRRK2–RAB7B axis in adipose tissue: The 2024 Autophagy report deployed an adipose-tropic nanoemulsion (DNL201-NE) to deliver an LRRK2 inhibitor in a TIGAR-overexpressing mouse model, correcting autophagy defects and lipid accumulation. This provides an in vivo implementation of pathway modulation that functionally engages RAB7B activity/state (Autophagy, Apr 2024, https://doi.org/10.1080/15548627.2024.2338576) (zhang2024tigarexacerbatesobesity pages 12-15).

9) Expert opinions and analysis
- Mechanistic synthesis: The combined evidence places RAB7B as a late endosome/TGN trafficking regulator that directly couples to the actomyosin system to coordinate vesicle transport and cell migration programs. Its cycling is constrained by TBC1D5 (with retromer enhancement), and its activity can be functionally modulated by upstream signaling hubs such as LRRK2 in disease-relevant tissues (borg2014anovelinteraction pages 1-2, borg2014anovelinteraction pages 4-7, distefano2018tbc1d5controlsthe pages 1-2, distefano2018tbc1d5controlsthe pages 3-6, zhang2024tigarexacerbatesobesity pages 12-15).
- Distinction from Rab7a is not merely paralogous redundancy but reflects divergent effector networks and routing priorities (Rab7a for lysosome maturation/autophagy; Rab7b for endosome→TGN retrograde movement and actomyosin coupling). This division likely underlies differing phenotypic consequences upon perturbation in immune cells, cancer models, and metabolic tissues (basuray2014rab7athemaster pages 4-7, borg2014anovelinteraction pages 1-2, distefano2018tbc1d5controlsthe pages 1-2).

10) Relevant statistics and data from recent studies
- Colocalization and motility: 69% Rab7b–myosin II colocalization; velocities 0.34 vs 0.19 vs 0.08 μm/s under graded myosin II inhibition; perinuclear clustering/enlargement of Rab7b+ Lamp-1+ late endosomes upon myosin II loss (J Cell Sci, 2014, https://doi.org/10.1242/jcs.155861) (borg2014anovelinteraction pages 4-7).
- FRAP kinetics: Rab7b t1/2 membrane recovery 19.01 ± 0.57 s (baseline) versus 26.25 ± 0.87 s with TBC1D10A coexpression (not a Rab7b GAP), reflecting altered cycling kinetics under different regulatory contexts (J Cell Sci, 2018, https://doi.org/10.1242/jcs.216630) (distefano2018tbc1d5controlsthe pages 3-6).
- Adipocyte disease model: TIGAR overexpression reduces active RAB7B on lipid droplets by ~2–3× and this correlates with suppressed lipid droplet lysosomal degradation; pharmacologic LRRK2 inhibition restores autophagy markers and reduces lipid accumulation in vivo (Autophagy, 2024, https://doi.org/10.1080/15548627.2024.2338576) (zhang2024tigarexacerbatesobesity pages 12-15).

Conclusions
Human RAB7B (UniProt Q96AH8) is a small Rab-family GTPase localized to late endosomes/lysosomes and the Golgi/TGN, where it regulates retrograde transport from late endosomes to the TGN and directly couples endosomal motility to the actomyosin cytoskeleton via myosin II. Its GTPase cycle is controlled by the GAP TBC1D5, whose activity is strengthened by retromer. Quantitatively, Rab7b colocalizes with myosin II on ~69% of vesicles and exhibits pronounced reductions in vesicle velocities upon myosin II inhibition; its membrane-binding dynamics are measurable by FRAP and sensitive to co-regulators. Recent work (2024) links RAB7B activity to autophagy and lipid metabolism through a TIGAR–LRRK2–RAB7B axis in adipocytes, with in vivo pharmacologic intervention demonstrating reversibility of pathological phenotypes. Together, these data delineate a specialized role for RAB7B—distinct from RAB7A—in endosome→TGN routing and cytoskeletal coordination with direct implications for immune signaling regulation, cell migration, and metabolic disease pathways (borg2014anovelinteraction pages 1-2, borg2014anovelinteraction pages 4-7, distefano2018tbc1d5controlsthe pages 1-2, distefano2018tbc1d5controlsthe pages 3-6, basuray2014rab7athemaster pages 4-7, zhang2024tigarexacerbatesobesity pages 12-15).

References

1. (borg2014anovelinteraction pages 1-2): Marita Borg, Oddmund Bakke, and Cinzia Progida. A novel interaction between rab7b and actomyosin reveals a dual role in intracellular transport and cell migration. Journal of Cell Science, 127:4927-4939, Nov 2014. URL: https://doi.org/10.1242/jcs.155861, doi:10.1242/jcs.155861. This article has 46 citations and is from a domain leading peer-reviewed journal.

2. (distefano2018tbc1d5controlsthe pages 1-2): Marita Borg Distefano, Linda Hofstad Haugen, Yan Wang, Harmonie Perdreau-Dahl, Ingrid Kjos, Da Jia, Jens Preben Morth, Jacques Neefjes, Oddmund Bakke, and Cinzia Progida. Tbc1d5 controls the gtpase cycle of rab7b. Journal of Cell Science, Sep 2018. URL: https://doi.org/10.1242/jcs.216630, doi:10.1242/jcs.216630. This article has 45 citations and is from a domain leading peer-reviewed journal.

3. (basuray2014rab7athemaster pages 4-7): Soumik BasuRay. Rab7a: the master regulator of vesicular trafficking. Biomedical Reviews, 25:67-81, Dec 2014. URL: https://doi.org/10.14748/bmr.v25.1049, doi:10.14748/bmr.v25.1049. This article has 2 citations.

4. (distefano2018tbc1d5controlsthe pages 3-6): Marita Borg Distefano, Linda Hofstad Haugen, Yan Wang, Harmonie Perdreau-Dahl, Ingrid Kjos, Da Jia, Jens Preben Morth, Jacques Neefjes, Oddmund Bakke, and Cinzia Progida. Tbc1d5 controls the gtpase cycle of rab7b. Journal of Cell Science, Sep 2018. URL: https://doi.org/10.1242/jcs.216630, doi:10.1242/jcs.216630. This article has 45 citations and is from a domain leading peer-reviewed journal.

5. (borg2014anovelinteraction pages 4-7): Marita Borg, Oddmund Bakke, and Cinzia Progida. A novel interaction between rab7b and actomyosin reveals a dual role in intracellular transport and cell migration. Journal of Cell Science, 127:4927-4939, Nov 2014. URL: https://doi.org/10.1242/jcs.155861, doi:10.1242/jcs.155861. This article has 46 citations and is from a domain leading peer-reviewed journal.

6. (zhang2024tigarexacerbatesobesity pages 12-15): Tianjie Zhang, Ke-gang Linghu, Jia Tan, Mingming Wang, Diao Chen, Yan Shen, Junchao Wu, Ming-jun Shi, Yuxia Zhou, Lei Tang, Lirong Liu, Zheng-Hong Qin, and Bing Guo. Tigar exacerbates obesity by triggering lrrk2-mediated defects in macroautophagy and chaperone-mediated autophagy in adipocytes. Autophagy, 20:1741-1761, Apr 2024. URL: https://doi.org/10.1080/15548627.2024.2338576, doi:10.1080/15548627.2024.2338576. This article has 18 citations and is from a domain leading peer-reviewed journal.

## Citations

1. borg2014anovelinteraction pages 1-2
2. borg2014anovelinteraction pages 4-7
3. zhang2024tigarexacerbatesobesity pages 12-15
4. https://doi.org/10.1242/jcs.155861;
5. https://doi.org/10.1242/jcs.216630
6. https://doi.org/10.14748/bmr.v25.1049;
7. https://doi.org/10.1080/15548627.2024.2338576
8. https://doi.org/10.1242/jcs.155861
9. https://doi.org/10.1242/jcs.155861,
10. https://doi.org/10.1242/jcs.216630,
11. https://doi.org/10.14748/bmr.v25.1049,
12. https://doi.org/10.1080/15548627.2024.2338576,